Inhibition of hepatitis c virus infection by dna aptamer against NS2 protein

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Gao, Yimin ^a   Yu, Xiaoyan ^a   Xue, Binbin ^a   Zhou, Fei ^a   Wang, Xiaohong ^a   Yang, Darong ^a,b   Liu, Nianli ^a,b   Xu, Li ^c   Fang, Xiaohong ^c   Zhu, Haizhen ^a,b  

^a HUNAN UNIVERSITY   (China)

^b HUNAN CANCER HOSPITAL   (China)

^c INSTITUTE OF CHEMISTRY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 5A; PEPTIDE APTAMER; VIRUS RNA;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; HEPATITIS C; IN VITRO STUDY; LIVER CELL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; REPLICON; RNA REPLICATION; VIRUS INHIBITION; VIRUS MUTATION;

ANTIVIRAL AGENTS; APTAMERS, NUCLEOTIDE; BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; ESCHERICHIA COLI; GENE EXPRESSION REGULATION, VIRAL; HEPACIVIRUS; HEPATOCYTES; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERON-BETA; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; RECOMBINANT PROTEINS; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84896504470     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090333     Document Type: Article

References (34)

1. Lavanchy D (2009) The global burden of hepatitis C. Liver Int (suppl. 1):74-81.
2. Hoofnagle JH, Seeff LB (2006) Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 355:2444-2451. (Pubitemid 44903748)
3. Monto A, Schooley RT, Lai JC, Sulkowski MS, Chung RT, et al. (2010) Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop. Am J Gastroenterol 105:989-1004.
4. Lorenz IC, Marcotrigiano J, Dentzer TG, Rice CM (2006) Structure of the catalytic domain of the hepatitis C virus NS2-3 protease. Nature 442:831-835. (Pubitemid 44258915)
5. Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM (2007) Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol 81:8374-8383. (Pubitemid 47242811)
6. Ma Y, Anantpadma M, Timpe JM, Shanmugam S, Singh SM, et al. (2011) Hepatitis C virus NS2 protein serves as a scaffold for virus assembly by interacting with both structural and nonstructural proteins. J Virol 85:86-97.
7. De la Fuente C, Goodman Z, Rice CM (2013) Genetic and functional characterization of the N-terminal region of the hepatitis C virus NS2 protein. J Virol 87:4130-4145.
8. Jiang J, Luo G (2012) Cell culture-adaptive mutations promote viral proteinprotein interactions and morphogenesis of infectious hepatitis C virus. J Virol 86:8987-8997.
9. Yi M, Villanueva RA, Thomas DL, Wakita T, Lemon SM (2006) Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci USA 103:2310-2315. (Pubitemid 43271666)
10. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, et al. (2005) Complete replication of hepatitis C virus in cell culture. Science 309:623-626. (Pubitemid 41033648)
11. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11:791-796. (Pubitemid 41021213)
12. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, et al. (2005) Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 102:9294-9299. (Pubitemid 40923557)
13. Ellington AD, Szostak JW (1990) In vitro selection of RNA molecules that binds specific ligands. Nature 346:818-822.
14. Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505-510.
15. Keefe AD, Pai S, Ellington A (2010) Aptamers as therapeutics. Nat Rev Drug Discov 9:537-550.
16. Tan W, Wang H, Chen Y, Zhang X, Zhu H, et al. (2011) Molecular aptamers for drug delivery. Trends Biotechnol 29:634-640.
17. Blight KJ, McKeating JA, Marcotrigiano J, Rice CM (2002) High permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 76:3001-13014.
18. Yang D, Meng X, Yu Q, Xu L, Long Y, et al. (2013) Inhibition of hepatitis C virus infection by DNA aptamer against envelop protein. Antimicrob Agents and Chemother 57:4937-4944.
19. Yang D, Xue B, Wang X, Yu X, Liu N, et al. (2013) 2-Octynoic acid inhibits hepatitis C virus infection through activation of AMP-activated Protein Kinase. PLoS One 8:e64932.
20. Yang D, Liu N, Zuo C, Lei S, Wu X, et al. (2011) Innate host response in primary human hepatocytes with hepatitis C virus infection. PLoS One 6:e27552.
21. Yi M, Ma Y, Yates J, Lemon SM (2007) Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. J Virol 81:629-638. (Pubitemid 46067890)
22. Zhu H, Zhao H, Collins CD, Eckerrode SE, Ruan Q, et al. (2003) Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line. Hepatology 37:180-1188.
23. Yi M, Ma Y, Yates J, Lemon SM (2009) Trans-complementation of an NS2 defect in a late step in hepatitis C virus (HCV) particle assembly and maturation. PLoS Pathogens 5:e1000403.
24. Pawlotsky JM (2012) New antiviral agents for hepatitis C. F1000 Biol Rep 4:5.
25. Halfon P, Locarnini S (2011) Hepatitis C virus resistance to protease inhibitors. J Hepatol 55:192-206.
26. Pawlotsky JM, Chevaliez S, McHutchison JG (2007) The hepatitis C virus lifecycle as a target for new antiviral therapies. Gastroenterology 132:979-1998.
27. Lorenz IC (2010) The hepatitis C virus nonstructural protein 2 (NS2): An upand-coming antiviral drug target. Viruses 2:1635-1646.
28. Ditzler MA, Bose D, Shkriabai N, Marchand B, Sarafiano SG, et al. (2011) Broad-spectrum aptamer inhibitors of HIV reverse transcriptase closely mimic natural substrates. Nucleic Acids Res 39:8237-8247.
29. Ramalingam D, Duclair S, Datta SAK, Ellington A, Rein A, et al. (2011) RNA aptamers directed to human immunodeficiency virus type 1 Gag protein bind to matrix and nucleocapsid domains and inhibit virus production. J Virol 85:305-314.
30. Hwang SY, Sun HY, Lee KH, Oh BH, Cha YJ, et al. (2012) 59-Triphosphate-RNA-independent activation of RIG-I via RNA aptamer with enhanced antiviral activity. Nucleic Acids Res 40:2724-2433.
31. Van Melckebeke H, Devany M, Di Primo C, Beaurain F, Toulme JJ, et al. (2008) Liquid-crystal NMR structure of HIV TAR RNA bound to its SELEX RNA aptamer reveals the origins of the high stability of the complex. Proc Natl Acad Sci USA 105:9210-9215.
32. Wheeler LA, Trifonova R, Vrbanac V, Basar E, McKernan S, et al. (2011) Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using C4 aptamer-siRNA chimeras. J Clin Invest 121: 2401-2412.
33. Moore MD, Cookson J, Coventry VK, Sproat B, Rabe L, et al. (2011) Protection of HIV neutralizing aptamers against rectal and vaginal nucleases: implications for RNA-based therapeutics. J Biol Chem 286:2526-2535.
34. Bentham M, Holmes K, Forrest S, Rowlands DJ, Stonehouse NJ (2012) Formation of higher-order foot-and-mouth disease virus 3Dpol complexes is dependent on elongation activity. J Virol 86:2371-2374.